CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
Buprenorphinedrug
Likely dose
Buprenorphine 0.2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01071538
NCT01071538Phase 2Completed
CompareCT.gov

Buprenorphine for Late-Life Treatment Resistant Depression

University of Pittsburgh·interventional·Posted Feb 19, 2010·Updated Mar 9, 2018

In Brief

A Phase 2 clinical trial evaluating Buprenorphine for Depression. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The goals of this pilot study are to gather data about the safety and clinical effect of low-dose buprenorphine in older adults with treatment resistant depression.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), Reckitt Benckiser LLC, National Center for Research Resources (NCRR)

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 19, 2010
Enrollment StartMay 1, 2010
Primary CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 16.4 years ago

Interventions

Buprenorphinedrug

Sublingual buprenorphine 0.2 mg will be used for the first week. The dose will be increased by 0.2 mg/week based on safety and clinical response up to a maximal dose of 1.6 mg/day.